169 related articles for article (PubMed ID: 32884297)
21. LncRNA SNHG14 regulates the DDP-resistance of non-small cell lung cancer cell through miR-133a/HOXB13 pathway.
Xu L; Xu Y; Yang M; Li J; Xu F; Chen BL
BMC Pulm Med; 2020 Oct; 20(1):266. PubMed ID: 33059643
[TBL] [Abstract][Full Text] [Related]
22. MiR-142-5p reverses the resistance to gefitinib through targeting HOXD8 in lung cancer cells.
Zhu W; Wang JP; Meng QZ; Zhu F; Hao XF
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4306-4313. PubMed ID: 32373967
[TBL] [Abstract][Full Text] [Related]
23. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
Sun C; Gao W; Liu J; Cheng H; Hao J
Respir Res; 2020 Aug; 21(1):210. PubMed ID: 32778129
[TBL] [Abstract][Full Text] [Related]
24. miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1.
Zhang H; Hu B; Wang Z; Zhang F; Wei H; Li L
Cancer Chemother Pharmacol; 2017 Nov; 80(5):973-984. PubMed ID: 28956120
[TBL] [Abstract][Full Text] [Related]
25. miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression.
Sui C; Meng F; Li Y; Jiang Y
J Transl Med; 2015 Apr; 13():132. PubMed ID: 25927928
[TBL] [Abstract][Full Text] [Related]
26. Downregulation of PEBP4, a target of miR-34a, sensitizes drug-resistant lung cancer cells.
Yu G; Zhong N; Chen G; Huang B; Wu S
Tumour Biol; 2014 Oct; 35(10):10341-9. PubMed ID: 25038915
[TBL] [Abstract][Full Text] [Related]
27. Upregulation of miR-146a increases cisplatin sensitivity of the non-small cell lung cancer A549 cell line by targeting JNK-2.
Pang L; Lu J; Huang J; Xu C; Li H; Yuan G; Cheng X; Chen J
Oncol Lett; 2017 Dec; 14(6):7745-7752. PubMed ID: 29344219
[TBL] [Abstract][Full Text] [Related]
28. miR-138 suppresses the proliferation, metastasis and autophagy of non-small cell lung cancer by targeting Sirt1.
Ye Z; Fang B; Pan J; Zhang N; Huang J; Xie C; Lou T; Cao Z
Oncol Rep; 2017 Jun; 37(6):3244-3252. PubMed ID: 28498463
[TBL] [Abstract][Full Text] [Related]
29. A novel circular RNA hsa_circRNA_103809/miR-377-3p/GOT1 pathway regulates cisplatin-resistance in non-small cell lung cancer (NSCLC).
Zhu X; Han J; Lan H; Lin Q; Wang Y; Sun X
BMC Cancer; 2020 Dec; 20(1):1190. PubMed ID: 33276753
[TBL] [Abstract][Full Text] [Related]
30. [MiR-192 confers cisplatin resistance by targeting Bim in lung cancer].
Zhang F; Li Y; Wu H; Qi K; You J; Li X; Zu L; Pan Z; Wang Y; Li Y; Li Y; Wang M; Shen W; Zhou Q
Zhongguo Fei Ai Za Zhi; 2014 May; 17(5):384-90. PubMed ID: 24854555
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-146a regulates cisplatin-resistance of non-small cell lung cancer cells by targeting NF-κB pathway.
Jiang P; Jia W; Wei X; Zhang X; Wang C; Li B; Song T; Yang J; Zhu D; Meng Y
Int J Clin Exp Pathol; 2017; 10(12):11545-11553. PubMed ID: 31966510
[TBL] [Abstract][Full Text] [Related]
32. LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4.
Hu B; Zhang H; Wang Z; Zhang F; Wei H; Li L
Cancer Biol Ther; 2017 Dec; 18(12):974-983. PubMed ID: 29020498
[TBL] [Abstract][Full Text] [Related]
33. MiR-1244 sensitizes the resistance of non-small cell lung cancer A549 cell to cisplatin.
Li W; Wang W; Ding M; Zheng X; Ma S; Wang X
Cancer Cell Int; 2016; 16():30. PubMed ID: 27073334
[TBL] [Abstract][Full Text] [Related]
34. CircPTK2 inhibits cell cisplatin (CDDP) resistance by targeting miR-942/TRIM16 axis in non-small cell lung cancer (NSCLC).
Wang Y; Wu Y; Xie S
Bioengineered; 2022 Feb; 13(2):3651-3664. PubMed ID: 35230201
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2.
Xie J; Yu F; Li D; Zhu X; Zhang X; Lv Z
Tumour Biol; 2016 Jan; 37(1):1197-204. PubMed ID: 26282001
[TBL] [Abstract][Full Text] [Related]
36. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y
Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072
[TBL] [Abstract][Full Text] [Related]
37. LncRNA HOST2 enhances gefitinib-resistance in non-small cell lung cancer by down-regulating miRNA-621.
Chen ZY; Liu HY; Jiang N; Yuan JM
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9939-9946. PubMed ID: 31799663
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-1 overexpression increases chemosensitivity of non-small cell lung cancer cells by inhibiting autophagy related 3-mediated autophagy.
Hua L; Zhu G; Wei J
Cell Biol Int; 2018 Sep; 42(9):1240-1249. PubMed ID: 29851226
[TBL] [Abstract][Full Text] [Related]
39. [SIRT1 Influences the Sensitivity of A549 Non-small Cell Lung Cancer Cell Line to
Cisplatin via Modulating the Noxa Expression].
Cao B; He X; Wang W; Shi M
Zhongguo Fei Ai Za Zhi; 2016 Feb; 19(2):57-63. PubMed ID: 26903157
[TBL] [Abstract][Full Text] [Related]
40. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.
Wang L; Shang X; Feng Q
Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
